Viemed Healthcare (VMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual general and special meeting scheduled for June 4, 2026, at the principal executive offices in Lafayette, Louisiana.
Meeting will address financial statements for fiscal years ended December 31, 2025 and 2024.
Shareholders can access meeting materials online or request printed copies at no cost.
Voting matters and shareholder proposals
Election of seven directors to serve until the next annual meeting.
Affirmation of Ernst & Young LLP as auditors for 2026 and authorization for the board to set their remuneration.
Ratification and approval of amendments to the 2024 Long Term Incentive Plan.
Advisory vote on executive compensation (say-on-pay).
Consideration of any other matters that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting for all director nominees and each proposal on the agenda.
Latest events from Viemed Healthcare
- Record Q2 2026 revenue and patient growth led to raised guidance and strong cash flow.VMD
Q2 2026 - Diversified home healthcare model, strong recurring revenue, and clear growth runway ahead.VMD
2nd Annual Lytham Partners Healthcare Investor Summit - Tech-enabled home-based care leader delivers strong growth, diversified services, and robust cash flow.VMD
Investor presentation - Q1 2026 revenue up 28% to $75.4M, with strong cash flow and raised full-year guidance.VMD
Q1 2026 - Shareholders will vote on director elections, auditor re-appointment, incentive plan changes, and executive pay.VMD
Proxy filing - Diversified home-based care platform delivers record growth, strong cash flow, and expansion opportunities.VMD
Investor presentation - Record 2025 growth and strong 2026 outlook with robust cash flow and share buyback.VMD
Q4 2025 - Record $58M Q3 revenue, 33% net income growth, and raised Q4 guidance signal strong momentum.VMD
Q3 2024 - Q2 revenue hit $55M, up 27% YoY, with strong EBITDA and growth outlook for Q3.VMD
Q2 2024